Discovery Life Sciences Now Offers Large-Scale Proteomic Services

US-based Discovery Life Sciences (Discovery) has launched its new Proteomic Services Division, which will serve pharmaceutical and biotech companies, government organizations, and non-profit and academic research centers. The company’s innovative offering includes both exploratory and targeted proteomics using the Seer Proteograph Product Suite, SCIEX LC-MS/MS systems, Olink Proximity Extension Assay (PEA), and Luminex xMAP platforms, according to a Dec. 14, 2022 company press release.

Discovery’s proteomic service laboratories are now integrated with the company’s short-and long-read genomic service laboratories and global commercial biorepository of hyper-annotated biospecimens. Meanwhile, as a part of its biomarker services expansion strategy, the company signed a multi-year agreement in January 2022 with Seer, a US-based life science company commercializing a disruptive new platform for proteomics, and SCIEX, a life science analytical technologies company, to form the Proteogenomics Consortium (PGC), a first-of-its-kind, according to a company press release (1), for large-scale plasma proteomic studies. The PGC combines the proprietary technologies and expertise of all three companies. The aim of the consortium is to offer unbiased, high-resolution proteogenomic services to help uncover novel biomarkers that can be mapped back to underlying genetic variations.

“We are very excited to open our doors to researchers and scientists worldwide and provide them access to Discovery’s highly-scaled, multi-omic services to advance their biomarker discovery, clinical development, and large-scale research programs,” said Michael Pisano, Discovery’s executive vice-president of Proteomics, in the company press release. “Our proteomic experts carefully designed, built, and optimized a comprehensive, platform-agnostic suite of leading-edge proteomic and proteo-genomic technologies to support all biomarker strategies, large-scale population studies, and biobank characterization projects.”

“The Proteogenomics Consortium strategically unites these highly advanced plasma proteomic technologies with our … expertise in short-and long-read genomics to add deep, unbiased proteomics data more easily to discovery, translational, and clinical studies, as well as large-scale population research programs,” said Glenn Bilawsky, CEO of Discovery, in the press release. “In addition, the PGC also enables the creation of new diagnostic tools for cancer, neurodegenerative, inflammatory, infectious diseases, and other therapeutic areas.”

Reference

1. Discovery Life Sciences, “Seer, Discovery Life Sciences, and SCIEX Announce First-Of-Its-Kind Proteogenomics Consortium for Large-Scale Studies,” Press Release, Jan. 10, 2022.

Source: Discovery Life Sciences